PortalPublikationenStrong impact of micrometastatic tumor cell load in patients...

Strong impact of micrometastatic tumor cell load in patients with esophageal carcinoma.

Standard

Strong impact of micrometastatic tumor cell load in patients with esophageal carcinoma. / König, Alexandra; Prenzel, Klaus L; Bogoevski, Dean; Yekebas, Emre F.; Bubenheim, Michael; Faithova, Lucia; Vashist, Yogesh; Gawad, Karim A.; Baldus, Stephan; Pantel, Klaus; Schneider, Paul M; Hölscher, Arnulf H; Izbicki, Jakob R.

in: ANN SURG ONCOL, Jahrgang 16, Nr. 2, 2, 2009, S. 454-462.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

König, A, Prenzel, KL, Bogoevski, D, Yekebas, EF, Bubenheim, M, Faithova, L, Vashist, Y, Gawad, KA, Baldus, S, Pantel, K, Schneider, PM, Hölscher, AH & Izbicki, JR 2009, 'Strong impact of micrometastatic tumor cell load in patients with esophageal carcinoma.', ANN SURG ONCOL, Jg. 16, Nr. 2, 2, S. 454-462. <http://www.ncbi.nlm.nih.gov/pubmed/19015923?dopt=Citation>

APA

König, A., Prenzel, K. L., Bogoevski, D., Yekebas, E. F., Bubenheim, M., Faithova, L., Vashist, Y., Gawad, K. A., Baldus, S., Pantel, K., Schneider, P. M., Hölscher, A. H., & Izbicki, J. R. (2009). Strong impact of micrometastatic tumor cell load in patients with esophageal carcinoma. ANN SURG ONCOL, 16(2), 454-462. [2]. http://www.ncbi.nlm.nih.gov/pubmed/19015923?dopt=Citation

Vancouver

König A, Prenzel KL, Bogoevski D, Yekebas EF, Bubenheim M, Faithova L et al. Strong impact of micrometastatic tumor cell load in patients with esophageal carcinoma. ANN SURG ONCOL. 2009;16(2):454-462. 2.

Bibtex

@article{0b516479b9ad44198a01495000726b9c,
title = "Strong impact of micrometastatic tumor cell load in patients with esophageal carcinoma.",
abstract = "BACKGROUND: To assess the role of immunohistochemically detectable nodal microinvolvement of patients with {"}curatively{"} resected esophageal carcinoma. METHODS: In 73 patients with resectable esophageal carcinoma [squamous cell carcinoma (SCC), n = 45 (61.6%); adenocarcinoma (AC), n = 28 (38.4%)] a total of 2174 lymph nodes (LN) were removed. In each of the 1958 LN classified as negative on conventional histopathology, immunohistochemistry was performed using the anticytokeratin antibody AE1/AE3. To determine the role of the amount of residual tumor load, the patients were grouped according to the percentage of LN affected with micrometastasis (0%, or =11%). RESULTS: Tumor cells were immunohistochemically detected in 47 LN (2.4%) from 25 (34.2%) patients. Five-year overall survival probability (5-YSP) of 30% in pN(0 )patients with detected occult tumor cells in LN was significantly worse than that in those without nodal microinvolvement (76%, P = 0.021), hereby resembling that of pN1-patients (24%, P = 0.84). Median overall survival in patients with no (0%), low (11%) micrometastatic tumor load was 43, 27, and 11 months, respectively. Substratification according to histological type showed that, in patients with AC, the presence of nodal microinvolvement had a significant impact on 5-YSP (0% versus 65%; P = 0.03), whereas in patients with SCC, differences of 5-YSP were only of borderline significance (24% versus 53%; P = 0.081). CONCLUSION: Minimal tumor cell load as assessed by the ratio of micrometastatically affected LN is a complementary tool for better risk stratification of patients with esophageal carcinoma.",
author = "Alexandra K{\"o}nig and Prenzel, {Klaus L} and Dean Bogoevski and Yekebas, {Emre F.} and Michael Bubenheim and Lucia Faithova and Yogesh Vashist and Gawad, {Karim A.} and Stephan Baldus and Klaus Pantel and Schneider, {Paul M} and H{\"o}lscher, {Arnulf H} and Izbicki, {Jakob R.}",
year = "2009",
language = "Deutsch",
volume = "16",
pages = "454--462",
journal = "ANN SURG ONCOL",
issn = "1068-9265",
publisher = "Springer New York",
number = "2",

}

RIS

TY - JOUR

T1 - Strong impact of micrometastatic tumor cell load in patients with esophageal carcinoma.

AU - König, Alexandra

AU - Prenzel, Klaus L

AU - Bogoevski, Dean

AU - Yekebas, Emre F.

AU - Bubenheim, Michael

AU - Faithova, Lucia

AU - Vashist, Yogesh

AU - Gawad, Karim A.

AU - Baldus, Stephan

AU - Pantel, Klaus

AU - Schneider, Paul M

AU - Hölscher, Arnulf H

AU - Izbicki, Jakob R.

PY - 2009

Y1 - 2009

N2 - BACKGROUND: To assess the role of immunohistochemically detectable nodal microinvolvement of patients with "curatively" resected esophageal carcinoma. METHODS: In 73 patients with resectable esophageal carcinoma [squamous cell carcinoma (SCC), n = 45 (61.6%); adenocarcinoma (AC), n = 28 (38.4%)] a total of 2174 lymph nodes (LN) were removed. In each of the 1958 LN classified as negative on conventional histopathology, immunohistochemistry was performed using the anticytokeratin antibody AE1/AE3. To determine the role of the amount of residual tumor load, the patients were grouped according to the percentage of LN affected with micrometastasis (0%, or =11%). RESULTS: Tumor cells were immunohistochemically detected in 47 LN (2.4%) from 25 (34.2%) patients. Five-year overall survival probability (5-YSP) of 30% in pN(0 )patients with detected occult tumor cells in LN was significantly worse than that in those without nodal microinvolvement (76%, P = 0.021), hereby resembling that of pN1-patients (24%, P = 0.84). Median overall survival in patients with no (0%), low (11%) micrometastatic tumor load was 43, 27, and 11 months, respectively. Substratification according to histological type showed that, in patients with AC, the presence of nodal microinvolvement had a significant impact on 5-YSP (0% versus 65%; P = 0.03), whereas in patients with SCC, differences of 5-YSP were only of borderline significance (24% versus 53%; P = 0.081). CONCLUSION: Minimal tumor cell load as assessed by the ratio of micrometastatically affected LN is a complementary tool for better risk stratification of patients with esophageal carcinoma.

AB - BACKGROUND: To assess the role of immunohistochemically detectable nodal microinvolvement of patients with "curatively" resected esophageal carcinoma. METHODS: In 73 patients with resectable esophageal carcinoma [squamous cell carcinoma (SCC), n = 45 (61.6%); adenocarcinoma (AC), n = 28 (38.4%)] a total of 2174 lymph nodes (LN) were removed. In each of the 1958 LN classified as negative on conventional histopathology, immunohistochemistry was performed using the anticytokeratin antibody AE1/AE3. To determine the role of the amount of residual tumor load, the patients were grouped according to the percentage of LN affected with micrometastasis (0%, or =11%). RESULTS: Tumor cells were immunohistochemically detected in 47 LN (2.4%) from 25 (34.2%) patients. Five-year overall survival probability (5-YSP) of 30% in pN(0 )patients with detected occult tumor cells in LN was significantly worse than that in those without nodal microinvolvement (76%, P = 0.021), hereby resembling that of pN1-patients (24%, P = 0.84). Median overall survival in patients with no (0%), low (11%) micrometastatic tumor load was 43, 27, and 11 months, respectively. Substratification according to histological type showed that, in patients with AC, the presence of nodal microinvolvement had a significant impact on 5-YSP (0% versus 65%; P = 0.03), whereas in patients with SCC, differences of 5-YSP were only of borderline significance (24% versus 53%; P = 0.081). CONCLUSION: Minimal tumor cell load as assessed by the ratio of micrometastatically affected LN is a complementary tool for better risk stratification of patients with esophageal carcinoma.

M3 - SCORING: Zeitschriftenaufsatz

VL - 16

SP - 454

EP - 462

JO - ANN SURG ONCOL

JF - ANN SURG ONCOL

SN - 1068-9265

IS - 2

M1 - 2

ER -